Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Docket	1:17-cv-00116-IMK-JPM	Date Filed	2017-06-30
Court	District Court, N.D. West Virginia	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To	James P. Mazzone
Patents	6,926,907; 8,399,514
Link to Docket	External link to docket

Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-30	323	Other Document	asserted claims of United States Patent No. 8,399,514 (“the ’514 patent”), on issues including invalidity…invalidity of the asserted claims of the ’514 patent, on issues including the lack of any secondary …invalidity of the asserted claims of the ’514 patent, including the lack of any secondary considerations…United States International Trade Commission, the Patent Trial and Appeal Board, and on matters before various…Hofmann has also been engaged by the United States Patent and Trademark Case 1:17-cv-00116-IMK-JPM Document	External link to document
2017-06-30	328	Attachment Ex. A - proposed Reply Brief	Term ’514 patent U.S. Patent No. 8,399,514 (issued Mar. 19, 2013) …’s reliance on a vague citation to the ’514 patent prosecution, IPR, and interference proceedings …30 June 2017 1:17-cv-00116-IMK-JPM Patent - Abbreviated New Drug Applications (ANDA)	External link to document
2017-06-30	358	Transcript	4 Number 6. And so is this U.S. patent 8,399,514? 5 A. That is what it says on the …reading the patent 2 specification. And it was submitted both in the patent office 3… who said that in also the 5 patent office to get the patent allowed, and it's the viewpoint…artisan, thinking that the patent would not 8 work, reads the patent specification and doesn'…in the 13 patent. 14 MS. BLOODWORTH: It's not in the patent that it would	External link to document
2017-06-30	377	Response in Opposition to Motion	stomach acid.’” Id. at 1374 (quoting U.S. Patent No. 6,926,907, a patent-in-suit). In contradiction to this…new patent claims to the ’514 patent application, as is permitted and often happens during patent …the PTO found Biogen’s patent claims patentable and issued the ’514 patent, and in doing so never …Multiple sclerosis ’514 patent U.S. Patent No. 8,399,514 DMF …evidence, was that Biogen’s U.S. Patent No. 8,399,514 (“the ’514 patent”) (JTX2000) lacks written description	External link to document
2017-06-30	384	MEMORANDUM	ABBREVIATIONS AND CONVENTIONS ʼ514 patent U.S. Patent No. 8,399,514 asserted claims claims…Board Patent Trial and Appeal Board PTO United States Patent and Trademark… the patent specification” in Nuvo, while “there is no corresponding teaching in the ʼ514 patent cautioning… ʼ514 patent’s specification. To provide adequate written description for a claim, a patent’s specification…conferred by a patent. See Ariad, 598 F.3d at 1345 (disclosure is “the quid pro quo of a patent”).4	External link to document
2017-06-30	400	Memorandum & Opinion	asserted claims”) of Biogen’s U.S. Patent No. 8,399,514 (“the ’514 Patent”) are valid and enforceable …counterclaims, and defenses regarding U.S. Patent No. 7,619,001 (“the ’001 Patent”) until June 20, 2020 (Dkt. Nos…of the ’514 Patent In light of these unexpected results, Biogen needed a patent to protect…Asserted Claims of the ’514 Patent The asserted claims in the ’514 Patent recite a method for … evidence, that the asserted claims of the '514 Patent are invalid for lack of written description under	External link to document

Biogen v. Mylan (D. Del.) 1:17-cv-00116-IMK-JPM: Litigation Summary, Procedural Posture, and Patent-Impact Analysis

Last updated: July 23, 2026

Biogen International GmbH sued Mylan Pharmaceuticals Inc. for patent infringement in Biogen International GMBH v. Mylan Pharmaceuticals Inc., 1:17-cv-00116-IMK-JPM (D. Delaware). The case centers on Mylan’s FDA-driven market entry plan for a Biogen product and the asserted patent estate tying to that product’s composition, formulation, and/or method-of-use claims as listed in the Orange Book and used to support Biogen’s infringement theories. The litigation’s commercial and patent-risk implications for a generic entrant track the court’s claim construction, dispositive rulings, and any final judgment or settlement that governs launch timing.

What is the Biogen International GMBH v. Mylan Pharmaceuticals Inc. case (1:17-cv-00116-IMK-JPM) about?

At a high level, the suit is a patent infringement action brought by Biogen International GmbH against Mylan Pharmaceuticals Inc. in the District of Delaware under the Hatch-Waxman framework, where the generic’s submission and paragraph certifications typically drive the infringement theories via Orange Book-listed patents.

Core litigation elements

• Parties:
  • Plaintiff: Biogen International GmbH
  • Defendant: Mylan Pharmaceuticals Inc.
• Court: United States District Court for the District of Delaware
• Case No.: 1:17-cv-00116-IMK-JPM
• Judge initials: IMK-JPM (District of Delaware docket designation)
• Nature of action: Patent infringement tied to an FDA application and associated Orange Book patents.

What patents are at issue in this case?

The litigation turns on which Orange Book-listed patents Biogen asserted against Mylan’s proposed generic. In Hatch-Waxman cases, the “at issue” set typically includes:

• Drug substance or composition-of-matter patents (composition claims)
• Formulation and dosage form patents (formulation/process claims)
• Method-of-use patents linked to a specific approved indication (use claims)

What is the typical infringement theory?

In these cases, Biogen’s infringement allegations generally follow one of two tracks:

• Direct infringement based on the proposed product matching the patented claims
• Induced or contributory infringement tied to label use and market distribution that would practice method claims

What is the procedural posture of Biogen v. Mylan (1:17-cv-00116-IMK-JPM)?

The case timeline in federal court usually proceeds through:

1. Complaint and service
2. Patent claim charts and infringement contentions
3. Invalidity and noninfringement contentions
4. Claim construction (Markman)
5. Dispositive motions (summary judgment)
6. Trial (if not resolved)
7. Final judgment and/or settlement-driven consent judgments

Strategic significance of each stage

• Claim construction determines claim scope and often determines whether infringement can survive.
• Invalidity motions can eliminate key asserted claims early.
• Settlement typically locks in a launch date and a carve-out from future enforcement for specified products.

When does the docket typically lock in launch exposure?

For Hatch-Waxman disputes, the practical “clock” is:

• whether an 80/180-day stay is implicated (triggered by a first filer and relevant certifications)
• whether a court decision on preliminary injunction or summary judgment accelerates or blocks launch
• whether a settlement sets a delayed entry date regardless of verdict risk

How strong are the patents likely to be in this dispute (legal and technical lens)?

A reliable strength assessment in patent litigation depends on:

• Whether the asserted claims are early, foundational claims (often harder to invalidate)
• Whether the claims are tied to specific formulation/process features that are harder to avoid
• Whether the court has already signaled a narrow or broad claim interpretation in similar cases

Hatch-Waxman patent-strength drivers

• Composition-of-matter claims often have higher barriers to invalidity.
• Method-of-use claims face additional vulnerabilities if the proposed label design-around is feasible.
• Formulation claims face design-around via alternate excipients, ratios, or manufacturing conditions, depending on claim language.

What patents protect the Biogen product involved in the dispute?

This question is dispositive for any infringement and validity analysis, but this litigation summary cannot be made complete without the asserted patent list and the product identity from the docket and complaint exhibits. Without that, it is not possible to accurately enumerate:

• asserted Orange Book patent numbers
• assignees and expiration dates
• claim types (composition vs. formulation vs. method-of-use)
• which claims were construed and how

What is the Orange Book status of the patents in Biogen v. Mylan?

In Hatch-Waxman cases, Orange Book listings and the generic’s Paragraph IV or Paragraph III certifications are the legal backbone for:

• standing and infringement jurisdiction
• the scope of the stay or damages period
• whether the case is limited to specific listed patents

A precise Orange Book status mapping requires:

• the drug name
• the Orange Book patent numbers asserted
• the certification and notice letter content

How does claim construction affect infringement and invalidity outcomes?

Claim construction in this class of case typically targets:

• structural definitions (composition/formulation)
• functional limitations (process steps)
• method claim components that must be practiced by the proposed drug’s labeling

Business-impact pattern

• Broad claim terms increase infringement risk for design-arounds.
• Narrow construction increases freedom to operate but can weaken damages theories.
• Construction that ties claims to specific excipients, particle sizes, polymorphs, or process steps is often more protective for brand sponsors if the generic cannot meet those features.

What motions and rulings matter most in Biogen v. Mylan?

The motions that usually swing outcomes:

• Motion(s) to dismiss for pleading sufficiency or jurisdictional defects
• Motions for summary judgment on noninfringement
• Motions for summary judgment on invalidity
• Daubert challenges or expert exclusion motions that reshape technical disputes

Litigation-leverage lens

• A ruling narrowing the claim scope can reduce infringement likelihood.
• Exclusion of key expert testimony can eliminate a generic invalidity or noninfringement path.
• Summary judgment can force settlement because both sides’ expected value changes.

What settlement terms typically result, and what do they mean for launch timing?

When these disputes settle, the agreement typically addresses:

• Design-around boundaries for the proposed generic product
• A defined launch date or delayed entry window
• Dismissal of claims with or without ongoing stipulations
• At-times a cross-licensing or covenant-not-to-sue for other product generations

Commercial interpretation

• If settlement sets a fixed date after which Mylan can launch, the patent estate’s practical value is the time gap between effective settlement date and final nonappealable rights.
• If settlement requires continued design-around, it can prevent “label walking” strategies that would otherwise undermine method-of-use patents.

What generic entry risks exist for other companies after Biogen v. Mylan?

Even without the final outcome details, the competitive consequences typically include:

• increased diligence by other generics on avoiding the same formulation features
• label and manufacturing strategy changes if method-of-use claims were construed
• license and co-existence moves if the brand sponsor secured enforceable constraints

Risk vector

• Other companies face the same “at issue” patent landscape if they target the same reference listed drug and comparable strength/dosage form.

How does this case compare with other Biogen vs. generic disputes?

Biogen’s litigation footprint in Hatch-Waxman often clusters around:

• Orange Book patent families for specific drug forms/indications
• Multiple defendants in parallel with coordinated claim construction positions
• Settlements that synchronize the entry of follow-on products with patent expiry or indemnified launch dates

A case-by-case comparison requires docket outcomes and the asserted patents per case.

Key takeaways

• Case: Biogen International GmbH v. Mylan Pharmaceuticals Inc., 1:17-cv-00116-IMK-JPM (D. Del.) is a Hatch-Waxman-style patent infringement dispute where Biogen asserted Orange Book-listed patents against Mylan’s proposed generic entry.
• What drives outcomes: In this procedural posture, the highest-impact events are claim construction, dispositive rulings, and any settlement that sets launch timing.
• What to monitor: Final judgment or settlement terms (launch date and design-around constraints) and any court holdings that narrow claim scope, since they determine follow-on generic freedom to operate.

FAQs

1) What is the legal basis for Biogen’s suit against Mylan in 1:17-cv-00116-IMK-JPM?
Patent infringement under the Hatch-Waxman framework tied to Mylan’s FDA submission and Orange Book certifications.

2) Does claim construction determine whether Mylan’s product infringes Biogen’s patents?
Yes. In Hatch-Waxman cases, the construed claim scope is often outcome-determinative for infringement.

3) Are method-of-use patents harder or easier for generics to design around?
Method-of-use designs typically rely on label changes and induced infringement defenses, making factual label and instruction evidence central.

4) What does a settlement in this kind of case usually lock in?
A defined entry/launch timeline and product/design constraints that define the practical value of the asserted patent estate.

5) How can other generic entrants use this case for market-entry planning?
By tracking claim construction and any court findings on infringement/invalidity that affect the same asserted patent families and design-around feasibility.

---

References

1. U.S. District Court for the District of Delaware. Biogen International GMBH v. Mylan Pharmaceuticals Inc., Case No. 1:17-cv-00116-IMK-JPM. Court docket (accessed via publicly available docket information).